Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

BACKGROUND: Carbonic anhydrase 9 (CA9) is a marker for hypoxia and acidosis, which is linked to a poor prognosis in human tumors. The purpose of this comparative analysis was to evaluate whether CA9 and VEGF expression are associated with survival outcomes in patients with metastatic colorectal canc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hong, Yong Sang, Cho, Hyeon Jin, Kim, Sun Young, Jung, Kyung Hae, Park, Ji Won, Choi, Hyo Seong, Oh, Jae Hwan, Kim, Byung Chang, Sohn, Dae Kyung, Kim, Dae Yong, Chang, Hee Jin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2719665/
https://ncbi.nlm.nih.gov/pubmed/19619339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-246
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados